US36338D1081 - Common Stock
0.1782 0 (-2.46%)
After market: 0.1824 +0 (+2.36%)
GALERA THERAPEUTICS INC
NASDAQ:GRTX (9/27/2023, 7:00:01 PM)After market: 0.1824 +0 (+2.36%)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Galera Therapeutics, Inc. is a clinical stage biotechnology company, which engages in developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. The company is headquartered in Malvern, Pennsylvania and currently employs 31 full-time employees. The company went IPO on 2019-11-07. The firm is focused on developing and commercializing a pipeline of therapeutic candidates to transform radiotherapy in cancer. Its lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic in development for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC) and for the reduction of esophagitis in patients with lung cancer. The company has completed Phase III Reduction in Oral Mucositis with Avasopasem Manganese (ROMAN) trial of GC4419 for the reduction of radiotherapy-induced SOM in patients with locally advanced HNC. Its second dismutase mimetic product candidate, rucosopasem manganese (GC4711), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).
GALERA THERAPEUTICS INC
45 Liberty Blvd., Suite 230
Malvern PENNSYLVANIA 19355
CEO: J. Mel Sorensen
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Pre-market stock movers are a hot topic on Tuesday as investors seek out the latest news on the biggest traders this morning!
MALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on...
Here you can normally see the latest stock twits on GRTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.